This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Renal Diseases, Other  • Diabetes Mellitus  • Alert me on articles by topic

What Do We Know, and What Do We Need to Learn?

Arch Intern Med. 2004;164:125-130.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

In patients with diabetes mellitus, advances in control of blood pressure and glycemia have led to reductions in neuropathy, retinopathy, and nephropathy. The results of large clinical trials indicate that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) slow the development and progression of diabetic nephropathy in patients with type 2 diabetes mellitus, almost certainly because of their interruption of the renin-angiotensin-aldosterone system. The Irbesartan in Patients with Type 2 Diabetes and MicroAlbuminuria Study and Microalbuminuria Reduction With VAL-sartan study demonstrated an especially remarkable influence in patients with microalbuminuria treated with the ARBs irbesartan and valsartan. When ARB doses are progressively increased beyond those needed to control blood pressure, proteinuria declines in a manner not paralleled by blood pressure reductions. Monotherapy with ARBs has an advantage over angiotensin-converting enzyme inhibitors in that the influence of ARBs on the angiotensin receptor cannot be overcome by activation of the renin-angiotensin-aldosterone system, . . . [Full Text of this Article]

ISSUE 1: BP CONTROL

ISSUE 2: WHEN SHOULD WE BEGIN TREATMENT?

ISSUE 3: DOSING

ISSUE 4: ACE INHIBITOR–ARB COMBINATIONS

ISSUE 5: ALDOSTERONE ANTAGONISM

ISSUE 6: THE GENETIC SUBSTRATE

CONCLUSIONS

Norman K. Hollenberg, MD, PhD
Department of Medicine and Radiology
Brigham and Women's Hospital
15 Francis St
Boston, MA 02115

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Leaking Capillaries and White Lung in Sepsis--Is Angiopoietin 2 the Culprit?: Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans. PLoS Medicine 3: e46, 2006
S.M. et al.
J. Am. Soc. Nephrol. 2006;17:1207-1217.
FULL TEXT